Using the plaque reduction assay, relatively simple bicyclic quinone molecules, as well as multiple copies thereof covalently attached to a long polyglutamate-based polymeric chain, were examined as new inhibitors of various naturally occurring strains of influenza A virus. The polymer-conjugated inhibitors were found to have a far greater potency (for some as high as two orders of magnitude when a long spacer arm was employed) than their corresponding parent molecules against the human Wuhan influenza strain. However, such polymeric inhibitors failed to exhibit higher potency compared to their small-molecule predecessors against the human Puerto Rico and avian turkey influenza strains. These observations, further explored by means of molecular modeling, reveal the previously unrecognized unpredictability of the benefits of multivalency, possibly because of poor accessibility of the viral targets to polymeric agents.
Introduction
Influenza A virus is highly transmissible and kills over 250,000 people worldwide each year. In the United States alone, some 20% of the population contracts the virus annually leading to countless missed days of work and school and tens of billions of dollars in associated costs. 1, 2 The two FDA-approved drugs for the treatment of influenza infections, Oseltamivir (Tamiflu™) and Zanamivir (Relenza™), have fallen short of expectations due to their mediocre activity in reducing the symptoms and duration of the infection, as well as emerging resistance in clinical isolates. 3, 4, 5 Thus new, more effective anti-influenza therapeutic agents are greatly needed.
One proposed strategy for generating more potent inhibitors of influenza is to utilize the benefits of multivalency. 2, 4, [6] [7] [8] [9] [10] [11] Conjugating multiple copies of influenza inhibitors to a flexible polymeric chain has been shown to result in multivalent interactions between the polymerattached inhibitors and the viral surface receptor proteins. 2, 4, [6] [7] [8] [9] [10] [11] These enhanced interactions, in turn, lead to a much stronger binding compared to that of the small-molecule parents stemming from favorable entropic factors; additionally, water-swollen polymeric chains may sterically hinder physical contacts between the virus and the target cell. 6 The foregoing benefits of multivalency for binding to influenza virus have been demonstrated for viral surface proteins with the natural ligand of hemagglutinin, Nacetylneuraminic (sialic) acid, and with the neuraminidase inhibitor Zanamivir. 2, 4, [6] [7] [8] [9] [10] [11] However, both of these compounds are structurally complex requiring many-step syntheses to become amenable to attachment to polymeric chains in order to investigate the effect of multivalency. 2, 4 They are also difficult to modify selectively and thus not optimal for structure-activity relationship (SAR) studies. In the present work, we instead have employed simple organic molecules 12 with anti-influenza properties to investigate the SAR of multivalency. In particular, stirred overnight at room temperature. The polymer was then isolated by precipitation in chloroform, washed with fresh chloroform to remove the unreacted anti-influenza agent, converted to the Na salt, and dialyzed against ddH 2 O in a 3,500-Da MW cutoff dialysis membrane for 24 hr to remove free salts and other impurities. TLC using a 3:1 (v/v) ethyl acetate:hexanes mixture confirmed purity and demonstrated the disappearance of the antiinfluenza agent's spot. Percent conjugation of the anti-influenza agent was calculated by means of 1 H-NMR in D 2 O using a Bruker 600 MHz instrument by comparing the ratio of the integration of a polymer peak with that of an anti-influenza agent's peak. In the case of a ~5% derivatization of the polymer with anti-influenza agent, 2.0 mg/0.010 mmol of DCC was added to the reaction mixture (2b, 5b, and 11). 
Synthesis of 17 and 18:
For 17, poly-L-glutamate Na salt was activated with propargylamine as described above and then the remaining carboxylates were converted to their free acids by reducing the pH, followed by the removal of water by freeze-drying. The resultant compound (40 mg) was dissolved in 1.5 mL of DMF, then N-hydroxysuccinimide (NHS) (79 mg, 0.69 mmol) was added with stirring, and the temperature was reduced to 0 ºC, followed by an addition of DIC (108 µL, 0.69 mmol). The reaction mixture was stirred on ice for 30 min and at room temperature for 3 hr, after which time an excess of aqueous NH 4 OH was added to displace the NHS-ester moieties resulting in a neutral poly-L-glutamine. 4, 17 Conjugation of 15 to the propargylamine-derivatized poly-L-glutamine was carried out via a cycloaddition as described above. For 18, poly-L-glutamate Na salt was derivatized with propargylamine in the same way as above, except that an excess of propargylamine (30 µL, 0.47 mmol) was added. For derivatization with inhibitor, the reaction was run as above, but only 0.1 mole-equivalents of 15 
Cells, Viruses, and Antiviral Assays
Madin-Darby canine kidney (MDCK) cells were purchased from the American Type Culture Collection (ATCC) and maintained as described by Haldar et al. Plaque reduction assays with MDCK cells were conducted to determine the half-maximal inhibitory concentration (IC 50 value) for each compound tested using a literature methodology.
2, 4
For plaque reduction assays investigating the effect of inhibitor in the solid growth agar, equal concentrations of the inhibitor were used during pre-incubation, infection, and in the nutrient agar formulation.
Docking simulations
The hemagglutinin structures of the Puerto Rico and X-31 strains of influenza A virus were obtained from the Protein Data Bank (PDB: 1RU7 and 2HMG, respectively). The docking studies for the hemagglutinin proteins and compounds 10 and 16 were performed with AutoDock Vina 18 and AutoDock Tools interface. All rotatable bonds in the ligands were allowed to rotate freely using the default settings. The search area, selected based on the previous studies with influenza small-molecule hemagglutinin inhibitors, 12, 19 covered the majority of the grooves of the protein.
The final results were selected based on the best binding modes.
Results and Discussion
Since the inherent structural complexities of Zanamivir and sialic acid do not allow for easy manipulations, for our SAR studies we chose to investigate whether there were simpler molecules also possessing anti-influenza activity. In the scholarly study by Bodian et al., 12 expanded by others, 19 docking simulations were performed to discover small organic molecules that bind to the hemagglutinin protein on influenza A viral strain X31 (H3N2) and stabilize the protein in its native conformation. This stabilization was proposed to hinder the conformational changes necessary for cell-viral membrane fusion, which is an essential step in the influenza infection cycle. 12 Specifically, the binding site explored was a region approximately half-way between the most outer tip of the hemagglutinin protein and the viral membrane near the fusion peptide. 12 These docking studies resulted in a group of benzoquinones and hydroquinones as potential ligands to bind to hemagglutinin and to inhibit the aforementioned conformational change. 12 One of the foregoing compounds, 5-hydroxynaphthalene-1,4-dione (1), was selected as a starting point for our studies. Using the plaque reduction assay method to test 1 for putative antiinfluenza activity against the Wuhan strain of the influenza A virus, we indeed found it to be a moderate inhibitor with an IC 50 value of 4.7 ± 1.5 µM (Table 1, 1 st entry). While other unnatural anti-hemagglutinin inhibitors exist (figure 2), [20] [21] [22] [23] [24] [25] all are structurally more complex than 1.
Therefore, we decided to continue our studies herein with compound 1.
In light of the previous studies with polymer-attached Zanamivir and sialic acid, 2, 4, 6-11
we next tested whether covalent conjugation of multiple copies of 1 to a polymeric chain would increase anti-influenza potency. To this end, 1 was attached to the physiologically benign and biodegradable polymer poly-L-glutamate at a ~10% loading (i.e., with approximately one tenth of all monomeric units being derivatized with the inhibitor). The resultant polymeric inhibitor 2a
exhibited an over 10-fold better IC 50 value compared to its monomeric counterpart 1 ( Table 1, 2 nd entry), presumably due to the phenomenon of multivalency. Interestingly, lowering the degree of loading of the inhibitor on the polymer from 10% to 5% (to yield 2b) failed to improve the antiviral potency ( Table 1 ), suggesting that the polymer-conjugated ligand molecules do not interfere with each other's ability to inhibit the virus.
One can readily envisage how steric constraints imposed by the polymeric chain may hinder the ability of the inhibitor to bind to its viral receptor, thus masking the true power of multivalency. This hypothesis was verified by inserting a nine-atom spacer arm between the polymer and 1, resulting in compound 3. As seen in Table 1 , this insertion indeed dramatically improved the IC 50 value: 20-fold over 2a and some 240-fold over 1.
To examine the generality of these findings, several structural analogs of 1, not previously identified as anti-influenza inhibitors, 12 were tested, along with their synthesized poly-L-glutamate conjugates, against the Wuhan influenza strain. 5-Hydroxy-3,4-dihydronaphthalene-1(2H)-one (4) and 2-hydroxy-3-methylnaphthalene-1,4-dione (7) both were found to be inhibitors, albeit much weaker ones than 1. Conjugating them to the polymer directly, i.e., with no spacer arm (to produce 5a or 5b depending on the degree of loading and 8, respectively) led to marked (7 and >3 fold, respectively) improvements in the antiviral potency (Table 1) . Moreover, as seen in Table 1 , when the nine-atom spacer arm was inserted to further distance the ligand from the polymeric chain (to form 6 and 9, respectively), the inhibitory potency in both cases rose another several-fold to reach the overall improvement compared to those of the parents 4 and 7 of 38 fold and >140 fold, respectively.
The same general trend of a dramatically enhanced inhibitory potency upon attachment to the polymeric chain via the spacer arm was observed with yet another analog of 1 tested, namely 5-hydroxy-2-methyl-1,4-naphthalenedione (10). This compound, which differs from 1 only by a methyl substituent in the benzoquinone portion of the molecule, exhibited an IC 50 value comparable to that of 1; converting it to 12 produced a 52-fold jump in inhibitory activity (Table   1) . Interestingly, however, in the case of 10 attached to the polymer with no spacer arm (11), no increase (and, in fact, a sizeable decline) in the potency was observed (Table 1) , illustrating how subtle the SAR is.
The poly-L-glutamate conjugate of 13 (in the absence of a nine-atom linker), 14, exhibited a greater than 30-fold improvement over its monomeric counterpart (Table 1) demonstrating that attachment through the 6C position in the naphthoquinone moiety does not have a deleterious effect on the inhibitor improvement; in fact, it generated the most potent nonlinker conjugated inhibitor.
In addition to a striking improvement in the inhibitory potency of the ligands upon conjugating them to poly-L-glutamate via the long spacer arm, their toxicity also diminished. In particular, both for 2a, 2b, and 3 vs. 1 and for 11 and 12 vs. 10 the cellular toxicity was at least an order of magnitude lower. For example, when compound 1 was used in the infection phase of the plaque reduction assay, cells that were incubated with the concentrations of inhibitor greater than, or equal to, 30 µM displayed obvious fatal demise. In contrast, cells incubated with even greater than 300 µM concentrations of polymer-attached inhibitors 2a, 2b, and 3 were healthy and seemingly unaffected by the presence of inhibitor. Presumably, sequestering the toxic small molecules (50% cell cytotoxicity concentration, CC 50 , of ~30 µM for 1 12 ) to the polymer prevents them from traversing the cellular membrane and exerting deleterious effects within the cell.
To determine to what extent the foregoing findings apply to other influenza A viruses, we selected two additional strains, namely the avian turkey and the human Puerto Rico ones. Both strains have different serotypes of the hemagglutinin and neuraminidase proteins compared to Wuhan's, leading to subtle differences in the amino acid makeup and structure of these proteins. 26 Using the plaque reduction assay, we tested the monomeric inhibitors 1, 7, 10, and 13, as well as those attached to poly-L-glutamate either via the nine-atom spacer arm (compounds 3, 6, and 12) or directly (14) . As in the case of the Wuhan strain, 1, 10, and 13 were substantial inhibitors of the viruses, whereas 7 was not (Table 2) , suggesting similarities in the receptors' binding sites of all three strains. And yet, in stark contrast to the observations made with the Wuhan strain (Table 1) , conjugation to the polymeric chains even via a long spacer arm not only failed to result in a significant improvement of the anti-influenza potency but, in the case of 1 and 10, actually made it markedly worse, i.e., increased the IC 50 values (Table 2 ). For 14, conjugation of the inhibitor to the polymer though the C6 position in the naphthoquinone also caused a substantial deterioration in potency for both turkey and Puerto Rico strains suggesting that the site of the linker's attachment is not entirely responsible for the reduction in inhibition.
We hypothesized that perhaps the addition of the linker group itself imposed new steric hindrances for binding of the inhibitor to the receptor sites on the turkey and Puerto Rico, but not the Wuhan, strains of the virus. This would inevitably lead to a diminished ability of the inhibitor to bind to its receptor when subsequently attached to poly-L-glutamate. To test this hypothesis, we focused on the compound 10 group of inhibitors and synthesized compound 16 containing the same chemical structure as the inhibitor plus the spacer arm portion of 12 but in the absence of polymer. As seen in Table 3 , 16 indeed exhibited a drastically poorer anti-influenza inhibition against all three viruses compared to the parent compound 10.
Thus the deteriorated inhibition potency upon attachment of the nine-atom spacer arm indeed may account for at least some of the inferior inhibition observed for compounds 3, 9, and 12 compared to their monomeric precursors 1, 7, and 10, respectively, against the turkey and Puerto Rico strains. However, in order for 12 to exhibit the multivalency benefits over 16 of greater than 100 fold (as it did with Wuhan strain, neutral poly-L-glutamine backbone, showed modest improvements for the turkey strain over its negatively charged analog 12 but failed to exhibit a great enhancement over the monomer 10 (Table 4) . Conversely, for the Wuhan strain, 17 demonstrated an almost 50-fold improvement over the monomer, similar to that afforded by compound 12 (Table 4) . Likewise, compound 18
(containing a partly negatively charged backbone) displayed no great enhancement for the turkey strain while exhibiting an almost 40-fold improvement over 10 for the Wuhan strain. These results indicate that the charge on the polymeric chain cannot account for the striking differences observed between the turkey and Wuhan strains for monomeric vs. polymer-attached inhibitors.
To determine whether the difference in improvements for polymer-attached conjugates over monomeric inhibitors between the Wuhan and turkey strains was an artifact of our biological assay, i.e., whether the inhibitor was brought into contact with the virus at the inappropriate time during infection, we performed an additional plaque assay with 10 and 12 present not only during the pre-incubation and binding (as is conventionally done) but also with the inhibitor in the agar overlay. This modality of the plaque reduction assay exposes cells and viruses to the inhibitor for the entirety of the first and subsequent infection phases leaving the inhibitor available for all steps in the viral cycle and not just for binding or endocytosis. In this experimental mode, the inhibitory effect of 10 and 12 for the Wuhan strain changed only modestly: IC 50 's of 2.4 ± 0.39 µM and 0.061 ± 0.045 µM, respectively, for incubation of inhibitor in the agar overlay vs. 5.7 ± 1.7 µM and 0.11 ± 0.070 µM for our conventional experiment. For the turkey strain, the inhibition by the monomer (10) improved more (IC 50 of 17 ± 1.0 µM when not included in the agar and 2.9 ± 0.49 µM when included in the agar) but the polymer-attached inhibitor's (12's) IC 50 exceeded 5 µM; these observations confirm that the lack of improvement for polymer-attached inhibitors against the turkey strain was not an artifact of our biological assay.
We then hypothesized that the preferred binding sites of the monomeric vs. the polymerattached inhibitors might be distinct between the strains, thus being responsible for their vastly different inhibitory properties. To explore this possibility, we ran in silico docking experiments to determine the preferred binding sites for the monomeric inhibitor 10 and the linker-attached inhibitor 16 for the Puerto Rico strain and a Wuhan surrogate strain, X-31 (both H3N2). Note that the X-31 strain has a 87% sequence identity for the HA1 strand of the hemagglutinin molecule compared to the Wuhan strain (the HA2 Wuhan sequence is unavailable) 27 , 28 (for comparison, the Puerto Rico's HA1 strand has just a 33% sequence identity 29 ). As seen in Figure   4A , for the X-31 strain both inhibitors bind in the same region of the hemagglutinin protein; this region coincides with the crystallographically determined binding site for tert-butyl hydroquinone (another fusion inhibitor described by Bodian et al. 12, 19 ). In stark contrast, for the Puerto Rico strain, inhibitors 10 and 16 bind in vastly distinct locations on the hemagglutinin protein, with as much as 40 Å separating them (Fig. 4B) . Note that 10 binds to a similar location on the Puerto Rico strain's hemagglutinin as both 10 and 16 in the X-31's protein; however, 16 on the Puerto Rico strain's hemagglutinin binds in a region that is closer to the viral envelope, thereby possibly hindering accessibility for the polymer-attached inhibitor.
One has to wonder why there are benefits of multivalency for all the compounds tested attached via a long spacer arm to a poly-L-glutamate for one strain of influenza, but not for the other two (Tables 1 and 2 ). It is unlikely that the observed differences in inhibition among viral strains are due to dissimilar spacing of hemagglutinin molecules along the viral surface among different strains. There ~400 hemagglutinin molecules on a given viral particle of roughly the same size regardless of the influenza virus strain. Since the mechanism of viral particle formation is the same for different strains, the spacing among hemagglutinin molecules on average should be similar as well. 26 The binding of the first polymer-attached inhibitor molecule to hemagglutinin is also unlikely to prevent binding of all the others. Although the binding of the first inhibitor molecule indeed might make it sterically impossible for a second, nearby counterpart to bind to hemagglutinin, that cannot be the case for more distant polymer-attached inhibitor molecules.
Since our (~10%-derivatized) polymeric chain contains some 50 randomly distributed inhibitor molecules, most of them should be sufficiently remote from the first one bound to interact with another hemagglutinin molecule.
The three influenza strains undoubtedly have some differences in the binding site for these inhibitors; 26 in the case of the turkey and Puerto Rico strains, these differences might interplay with the polymer and/or linker deleteriously to weaken the binding of the conjugated inhibitor to the virus. Additionally, the topology of the viral surface might introduce accessibility problems for the inhibitors once they are attached to the bulky, hydrated polymeric chain. In previous studies of the effect of multivalency on anti-influenza inhibitors, the receptor of the multivalent ligand was proximal to the solvent-exposed outer edge of the surface protein. 2, 4, [6] [7] [8] [9] [10] [11] Although the exact location of binding of 1 and its analogs to hemagglutinins in the strains studied herein is unknown, our docking studies (Fig. 4) predict that for 10 and 16 the site is located approximately half-way down the protein for the X-31 strain and close to the viral envelope for the linker-attached inhibitor (16) on the Puerto Rico strain. 12 Perhaps while a small molecule readily accesses regions down the stock of the protein, conjugation to a bulky polymeric chain hampers the access below the dense canopy of proteins on the viral surface.
The concept of multivalency stipulates that several simultaneous interactions of ligands and receptors should result in a stronger, multipoint inhibitor-virus binding and hence give rise to more potent inhibitors ( Figure 5 ). 6 Our results herein suggest, however, that this is indeed the case only if attaching an inhibitor to a polymeric chain does not impose negative spatial constraints not outweighed by the inherent benefits of multivalency. Since it is unknown in advance whether this will be the case, our data illustrate that the superiority of multivalent inhibitors of a virus compared to their monovalent predecessors cannot be automatically assumed. 
